This is what analysts have to say about Recro Pharma, Inc. (NASDAQ:REPH) after last week.

June 9, 2018 - By Ellis Scott

Recro Pharma, Inc. (NASDAQ:REPH) LogoInvestors sentiment increased to 2.37 in Q1 2018. Its up 0.87, from 1.5 in 2017Q4. It is positive, as 5 investors sold Recro Pharma, Inc. shares while 14 reduced holdings. 23 funds opened positions while 22 raised stakes. 10.95 million shares or 14.40% more from 9.57 million shares in 2017Q4 were reported.
Parametric Portfolio Associates Ltd Liability has invested 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Bb&T Corporation invested 0.01% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Legal & General Public Limited has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). State Of Wisconsin Investment Board holds 0% or 11,000 shares in its portfolio. Barclays Public Limited Co reported 4,974 shares. Walleye Trading Ltd Liability holds 19,600 shares. Bancshares Of Montreal Can owns 4,328 shares. Cadence Management Limited Liability Corp accumulated 141,942 shares or 0.1% of the stock. Bancshares Of Ny Mellon Corp invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Schwab Charles Mgmt reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). 260,352 were accumulated by Kingdon Cap Mgmt Ltd Limited Liability Company. Vanguard Group Inc reported 661,473 shares. Sphera Funds Ltd holds 0.61% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH) for 364,197 shares. Gp has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). The California-based Lyon Street Lc has invested 3.64% in Recro Pharma, Inc. (NASDAQ:REPH).

Since December 12, 2017, it had 0 insider buys, and 8 insider sales for $4.62 million activity. $115,139 worth of Recro Pharma, Inc. (NASDAQ:REPH) was sold by SCP Vitalife Partners (Israel) II – L.P.. Broadfin Healthcare Master Fund Ltd sold $1.09M worth of stock. On Friday, March 9 Berelowitz Michael sold $78,347 worth of Recro Pharma, Inc. (NASDAQ:REPH) or 7,500 shares.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 4 analysts covering Recro Pharma (NASDAQ:REPH), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma has $21.2500 highest and $1100 lowest target. $15.81’s average target is 198.87% above currents $5.29 stock price. Recro Pharma had 5 analyst reports since February 13, 2018 according to SRatingsIntel. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by Oppenheimer on Tuesday, February 13. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, February 28. The rating was maintained by Oppenheimer on Thursday, May 10 with “Buy”. Berenberg initiated Recro Pharma, Inc. (NASDAQ:REPH) on Thursday, April 19 with “Buy” rating. Below is a list of Recro Pharma, Inc. (NASDAQ:REPH) latest ratings and price target changes.

24/05/2018 Broker: Janney Capital Rating: Buy New Target: $11.0000
10/05/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0000 Maintain
19/04/2018 Broker: Berenberg Rating: Buy New Target: $21.2500 Initiate
28/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
13/02/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Initiate

The stock decreased 0.19% or $0.01 during the last trading session, reaching $5.29. About 251,910 shares traded. Recro Pharma, Inc. (NASDAQ:REPH) has declined 32.73% since June 9, 2017 and is downtrending. It has underperformed by 45.30% the S&P500.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $108.49 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Streetinsider.com which released: “Pre-Open Movers 05/24: (BW) (SMRT) (WSM) Higher; (REPH) (QUIK) (MLNT) Lower (more…)” on May 24, 2018, also Seekingalpha.com with their article: “Key events next week – healthcare” published on May 18, 2018, Globenewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Recro Pharma …” on June 03, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: Businesswire.com and their article: “Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Recro Pharma, Inc …” published on June 06, 2018 as well as Businesswire.com‘s news article titled: “REPH INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Recro Pharma, Inc …” with publication date: June 01, 2018.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: